Momenta Refocuses On Three Novel Autoimmune Drugs In Transition To More Traditional Biotech
Momenta will invest in three novel drugs and end development of all but two late-stage biosimilars under a new business strategy. The company is reducing its workforce by 50%, or about 110 employees.
You may also be interested in...
Surprise! Mylan's Copaxone Generic Sets Teva Up For A Struggle
FDA cleared Mylan's generic version of Copaxone 40mg even after management warned investors not to expect action until 2018. Mylan said it will launch "imminently, but Teva said a launch ahead of the pending appeals case would be "at risk."
Deal Watch: Taking Care Of Business Before J.P. Morgan
Under Momenta/CSL autoimmune partnership, Momenta can opt in to co-development or commercialization on recombinant Fc receptor modulator or just earn a revenue stream from CSL’s efforts with the preclinical candidate. Pieris and Servier sign broad-based immuno-oncology collaboration, while Arena hands off the disappointing Belviq to Eisai.
Roche Pharma CEO Graham On Growth Prospects, Policy Pressures, Alzheimer’s And More
“I don’t think anybody can afford to not be in the Alzheimer’s race,” Graham said in one of her first public appearances since becoming CEO of Roche pharmaceuticals.